05.16.16
Sandra Rojas-Caro, M.D. has been appointed chief medical officer at Aeglea BioTherapeutics, Inc., a biotechnology company developing enzyme-based therapeutics to treat inborn errors of metabolism and cancer.
Dr. Rojas-Caro will oversee the medical strategy and clinical development of Aeglea’s pipeline. She brings more than 15 years of protein therapeutics and small molecule drug development experience.
Previously, she served as group vice president of Clinical Research and Development at Synageva BioPharma, where she was instrumental in leading the medical team and contributed to the approval of Kanuma (sebelipase alpha) for the treatment of lysosomal acid lipase deficiency, and advancing the clinical development of other metabolism programs. Following the acquisition of Synageva by Alexion, Dr. Rojas-Caro served as vice president and R&D project team leader for SBC-103, where she supported the integration post-merger. Dr. Rojas-Caro also held roles in clinical and translational research with increasing levels of responsibility at Roche, Array BioPharma and Pfizer.
“We are extremely pleased to have Dr. Rojas-Caro join the Aeglea leadership team as chief medical officer. She brings expertise and knowledge in the area of protein-based rare disease therapeutics and metabolism, and a track record of advancing the clinical development of needed drug therapies. Her leadership is anticipated to bring us closer to realizing our goal of improving the lives of patients,” said David G. Lowe, PhD, co-founder, president and chief executive officer of Aeglea.
Dr. Rojas-Caro will oversee the medical strategy and clinical development of Aeglea’s pipeline. She brings more than 15 years of protein therapeutics and small molecule drug development experience.
Previously, she served as group vice president of Clinical Research and Development at Synageva BioPharma, where she was instrumental in leading the medical team and contributed to the approval of Kanuma (sebelipase alpha) for the treatment of lysosomal acid lipase deficiency, and advancing the clinical development of other metabolism programs. Following the acquisition of Synageva by Alexion, Dr. Rojas-Caro served as vice president and R&D project team leader for SBC-103, where she supported the integration post-merger. Dr. Rojas-Caro also held roles in clinical and translational research with increasing levels of responsibility at Roche, Array BioPharma and Pfizer.
“We are extremely pleased to have Dr. Rojas-Caro join the Aeglea leadership team as chief medical officer. She brings expertise and knowledge in the area of protein-based rare disease therapeutics and metabolism, and a track record of advancing the clinical development of needed drug therapies. Her leadership is anticipated to bring us closer to realizing our goal of improving the lives of patients,” said David G. Lowe, PhD, co-founder, president and chief executive officer of Aeglea.
